Trial Profile

A Phase I clinical study of orally-dosed HBW-3220 in patients with relapsed/refractory B-cell lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HBW-3220 (Primary)
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Small cell lung cancer; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

10 Apr 2024 Results assessing efficacy and safety of HBW-3220 capsules in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, presented at the 115th Annual Meeting of the American Association for Cancer Research
10 Jul 2023 New trial record
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com